Blood Cancer Journal

Papers
(The TQCC of Blood Cancer Journal is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
CAR-T cell therapy: current limitations and potential strategies939
Acute myeloid leukemia: current progress and future directions326
Multiple myeloma current treatment algorithms183
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma136
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)127
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple m125
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies103
CAR T-cell therapy in multiple myeloma: more room for improvement100
New directions for emerging therapies in acute myeloid leukemia: the next chapter97
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment96
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia93
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study89
Acute promyelocytic leukemia current treatment algorithms81
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia79
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups78
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report78
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies76
Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm76
Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century69
Chromosome 1q21 abnormalities in multiple myeloma68
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma67
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage67
FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm66
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma64
The high cost of prescription drugs: causes and solutions64
Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study62
Extramedullary disease in multiple myeloma: a systematic literature review60
Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response59
Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study54
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality53
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis51
Core binding factor acute myelogenous leukemia-2021 treatment algorithm51
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up 50
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis49
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy49
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab49
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)48
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life47
AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia47
Genetic and epigenetic determinants of diffuse large B-cell lymphoma46
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma45
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis44
Extramedullary disease in multiple myeloma44
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantati41
Diffuse large B-cell lymphoma: new targets and novel therapies40
Comprehensive Review of AL amyloidosis: some practical recommendations40
Immune-based therapies in the management of multiple myeloma39
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study38
B-cell maturation antigen expression across hematologic cancers: a systematic literature review38
CREBBP and STAT6 co-mutation and 16p13 and 1p36 loss define the t(14;18)-negative diffuse variant of follicular lymphoma36
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera36
Management of chronic myeloid leukemia in 2023 – common ground and common sense36
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results36
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis35
Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment35
Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis35
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse34
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia34
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden34
A simple additive staging system for newly diagnosed multiple myeloma33
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements33
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)32
Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study32
Venetoclax for the treatment of translocation (11;14) AL amyloidosis32
Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML32
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial32
Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up31
Differentiation therapy for myeloid malignancies: beyond cytotoxicity31
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program30
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia30
Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden30
A clinical perspective on plasma cell leukemia; current status and future directions30
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo30
Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma29
Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab29
High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions29
“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience29
Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma29
Mutations and thrombosis in essential thrombocythemia29
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine29
Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia28
Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma28
Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation28
Genomic insights into the pathogenesis of Epstein–Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing28
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study27
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns27
Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 202127
EVI1 dysregulation: impact on biology and therapy of myeloid malignancies27
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice27
Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18–65 years: NILG ALL 10/0727
Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up26
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program26
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points26
Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma26
Impact of COVID-19 in patients with multiple myeloma based on a global data network25
Financial toxicity in hematological malignancies: a systematic review25
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-1925
Fusion gene map of acute leukemia revealed by transcriptome sequencing of a consecutive cohort of 1000 cases in a single center24
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells24
Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 201924
Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy24
Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review24
Global burden of hematologic malignancies and evolution patterns over the past 30 years24
The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML23
Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study23
MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients23
Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression23
Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome22
Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia22
Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication22
Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies22
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study22
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma22
Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma22
Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia22
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL21
Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia21
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia21
Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients21
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee20
“Direct to Drug” screening as a precision medicine tool in multiple myeloma20
Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities20
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib20
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)19
Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients19
Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms19
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel19
Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera19
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study18
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy18
Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement18
Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells18
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis18
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy18
Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update18
Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis18
Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype17
A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL17
Cutaneous manifestations of monoclonal gammopathy17
Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins17
Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients17
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients17
High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma17
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib17
Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia16
Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment16
Genomic characterization of functional high-risk multiple myeloma patients16
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma16
Therapeutic targeting of the inflammasome in myeloid malignancies16
Preclinical development of CD126 CAR-T cells with broad antitumor activity16
An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)16
Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism16
A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study16
Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma16
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor16
Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia15
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies15
Smoldering multiple myeloma current treatment algorithms15
Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia15
FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome15
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma14
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial14
Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia14
Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients14
Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis14
γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation14
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial14
Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients14
Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT14
HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias14
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action14
The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 201814
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies14
Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota13
Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis13
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy13
Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation13
Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome13
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review13
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma13
Infectious complications of bispecific antibody therapy in patients with multiple myeloma13
Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression13
Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma13
0.076505899429321